Holen Sie sich die Stockscreener-App
0.2225
13.32%
-0.0342
Schlusskurs vom Vortag:
$0.2567
Offen:
$0.258
24-Stunden-Volumen:
823.31K
Relative Volume:
1.07
Marktkapitalisierung:
$10.19M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-15.72M
KGV:
-0.5685
EPS:
-0.3914
Netto-Cashflow:
$-9.68M
1W Leistung:
-11.43%
1M Leistung:
-4.51%
6M Leistung:
-71.80%
1J Leistung:
-75.49%
1-Tages-Spanne:
$0.221
$0.2792
1-Wochen-Bereich:
$0.221
$0.2811
52-Wochen-Spanne:
$0.2178
$1.73
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
Firmenname
Akari Therapeutics Plc Adr
Sektor
Branche
Telefon
(929) 274-7510
Adresse
401 EAST JACKSON STREET, TAMPA
Compare AKTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKTX
Akari Therapeutics Plc Adr
|
0.2225 | 11.75M | 0 | -15.72M | -9.68M | -0.3914 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.59 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
747.28 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.43 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.75 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.52 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2025-07-18 | Eingeleitet | Maxim Group | Buy |
| 2019-01-04 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Neutral |
| 2017-09-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2017-05-31 | Hochstufung | Chardan Capital Markets | Sell → Neutral |
| 2017-04-17 | Bestätigt | Chardan Capital Markets | Sell |
| 2016-07-11 | Eingeleitet | Chardan Capital Markets | Sell |
Alle ansehen
Akari Therapeutics Plc Adr Aktie (AKTX) Neueste Nachrichten
Akari Therapeutics marks one year under CEO Gaslightwala - Investing.com
Akari Therapeutics adds Dana-Farber expert to advisory board - Investing.com
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board - Finviz
Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board - Sahm
Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference - Sahm
Will Akari Therapeutics Plc Depositary Receipt outperform the market in YEAR2025 Earnings Impact & Free High Return Stock Watch Alerts - mfd.ru
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline - ChartMill
Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - Sahm
Akari Therapeutics (NASDAQ: AKTX) seeks approval for major warrant exercises - Stock Titan
Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors - Sahm
Curious about the stocks that are showing activity after the closing bell on Monday? - Chartmill
Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026 - GlobeNewswire Inc.
Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026 - Sahm
Akari Therapeutics to Present at the 2026 Biotech Showcase - Sahm
Why Vanda Pharmaceuticals Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Sahm
Akari Therapeutics Plc ADR (AKTX) Stock Sees a-0.57% Decrease - News Heater
Akari Therapeutics advances ADC oncology program with novel payload By Investing.com - Investing.com South Africa
Akari Therapeutics advances ADC oncology program with novel payload - Investing.com India
Operating cash flow per share of Akari Therapeutics Plc Sponsored ADR – FWB:CLA - TradingView — Track All Markets
AKTX SEC FilingsAkari Therapeutics Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Short Interest in Akari Therapeutics PLC (NASDAQ:AKTX) Expands By 650.6% - Defense World
Akari begins GMP manufacturing of lead ADC program with WuXi XDC - Investing.com
Akari begins GMP manufacturing of lead ADC program with WuXi XDC By Investing.com - Investing.com South Africa
Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial - Sahm
Akari Therapeutics Releases Virtual Investor “What This Means” Segment - Sahm
Akari Therapeutics (Nasdaq: AKTX) sells 10M ADSs and issues new warrants - Stock Titan
Akari Therapeutics raises $5 million in at-market offering By Investing.com - Investing.com South Africa
Akari Therapeutics raises $5 million in at-market offering - Investing.com India
Akari Therapeutics stock rises on promising pancreatic cancer drug data By Investing.com - Investing.com South Africa
Akari Therapeutics stock rises on promising pancreatic cancer drug data - Investing.com
Views of Wall Street’s Leading Experts on Moderna Inc - setenews.com
Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment - Sahm
Akari Therapeutics receives Nasdaq notice for minimum bid price non-compliance - Investing.com
Akari Therapeutics receives Nasdaq notice for minimum bid price non-compliance By Investing.com - Investing.com South Africa
Akari Therapeutics Announces Release of the Next CEO Corner Segment - Sahm
Tops & Flops Stocks - sharewise.com
Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer - Finviz
Akari Therapeutics appoints Kameel Farag as interim CFO By Investing.com - Investing.com South Africa
Akari Therapeutics appoints Kameel Farag as interim CFO - Investing.com
[DEF 14A] Akari Therapeutics Plc Definitive Proxy Statement - Stock Titan
[S-1] Akari Therapeutics Plc Files IPO Registration Statement | AKTX SEC FilingForm S-1 - Stock Titan
Insiders Re-Evaluate Their US$1.81m Stock Purchase As Akari Therapeutics Falls To US$19m - Sahm
Why Akari Therapeutics Plc Depositary Receipt stock appeals to analystsWall Street Watch & Verified Momentum Stock Watchlist - newser.com
[PRE 14A] Akari Therapeutics Plc Preliminary Proxy Statement - Stock Titan
Akari Therapeutics Plc ADR (AKTX) looking to reclaim success with recent performance - setenews.com
Akari Therapeutics forms scientific advisory board with Dr. Hurvitz By Investing.com - Investing.com South Africa
Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP - The Manila Times
What Wall Street predicts for Akari Therapeutics Plc Depositary Receipt stock priceMarket Performance Summary & Weekly Breakout Stock Alerts - newser.com
Akari Therapeutics launches CEO Corner to enhance investor communications By Investing.com - Investing.com India
Finanzdaten der Akari Therapeutics Plc Adr-Aktie (AKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Akari Therapeutics Plc Adr-Aktie (AKTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gaslightwala Abizer | CEO |
Aug 22 '25 |
Buy |
0.93 |
8,000 |
7,440 |
295,574 |
| Gaslightwala Abizer | CEO |
Aug 25 '25 |
Buy |
0.90 |
3,000 |
2,700 |
298,574 |
| Gaslightwala Abizer | President & CEO |
Jun 24 '25 |
Buy |
1.16 |
5,203 |
6,035 |
277,574 |
| Gaslightwala Abizer | President & CEO |
Jun 23 '25 |
Buy |
1.15 |
943 |
1,084 |
272,371 |
| Gaslightwala Abizer | President & CEO |
Jun 20 '25 |
Buy |
1.20 |
10,000 |
12,000 |
271,428 |
| Gaslightwala Abizer | President & CEO |
Jun 17 '25 |
Buy |
1.20 |
15,000 |
18,000 |
261,428 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):